A Longitudinal Multidimensional Population Study on Brain Aging (InveCeAb)

December 10, 2015 updated by: Antonio Guaita, MD, Fondazione Golgi Cenci

A Longitudinal Population Study on Brain Aging and Mental Performances for the 1935-1939 Born People Living in Abbiategrasso (a Small Town Near Milan)

Longitudinal observational study of cognitive functions, physical health and biological parameters in the whole population living in Abbiategrasso born between 1935 and 1939,1773 subjects, followed for six years in order to know the prevalence and the incidence of dementia and risk and protective factors of normal and pathological mental aging.

The peculiarities of this study that must assure the outcome efficacy are:

  • Selected age: since 70-75 years old people represents a transition age from adulthood to old age, it is of special interest to study the evolution of psychic and physical functions of this population
  • Whole population not a sample study
  • Location: the small area involved (Abbiategrasso is a town of 30.000 inhabitants)can contribute to guarantee more homogeneity among the subjects and reduce undesired variability
  • multidimensional assessment(biological, clinical, social, psychological data collected) After initial screening, the recruited population will be followed up for two more times (every two years )

Study Overview

Status

Completed

Detailed Description

Background:

Dementia is one of the most troubling neurodegenerative syndrome whose prevalence and incidence is strongly increasing. The etiology and physiopathology of the process that causes dementia are still controversial and largely unknown. So it is of paramount importance to isolate risk and protection factors related to dementia syndrome and Alzheimer disease. These meager known factors (biological, as well as social and neuropsychological) can be better investigated through a multidimensional longitudinal study in a homogeneous population by age and place.

Method:

People belonging to the selected population (1773 subjects living in Abbiategrasso and born between 1935 - 1939) were invited to participate at a comprehensive assessment which was divided in two appointments:

  • a first appointment (about 1 hour and half) for blood sample, social questionnaire, anthropometric and walking speed evaluation ;
  • a second one (2 hours)for clinical examination and neuropsychological assessment of mood and cognitive function.

Recruitment. People were recruited through several steps:

  • involvement of the family doctor;
  • a general call, based on age group(1935,1936, 1937, 1938, 1939), since to be born in the same year is an identity mark for these generations;
  • kick-off meetings for each age class explaining aims and methods of the research, followed by a party with music, plays and some lotteries
  • a letter with the date of the appointment followed by the phone call whenever the phone number is available
  • further letters and call until either a rejection or an appointment was taken.

Assessment. Professionals and instruments:

  • Trained interviewers, one social worker and two nurses, administer the social questionnaire that is partly derived from the CERAD and from other longitudinal studies.
  • Trained psychologists administer a neuropsychological battery exploring mood (GDS 15 items), verbal and visual memory (Rey 15-item Memory Test, and the Rey-Osterrieth Complex Figure Test (ROCF) recall; Babcock Story Recall Test ), executive function ( TMTA and TMTB; copy of ROCF), attention (Numerical Attention), abstract reasoning (Raven's Coloured Progressive Matrices), screening cognitive test (Clock test and MMSE).
  • Clinical interview and visit are executed by expert geriatricians, members of the same geriatric staff who apply diagnostic criteria for dementia (DSM IV), Alzheimer disease (NINCDS ADRDA diagnostic criteria); Vascular dementia (NINDS -AIREN criteria); Lewy Body dementia (third report, DLB consortium); frontotemporal dementia ( 2002 modified Consensus conference criteria). Other cognitive problems were classified as Mild Cognitive Impairment (MCI) following Petersen's criteria or Cognitive Impairment No Dementia (CIND) when cognitive impairments are in areas other than memory and they do not meet whole criteria for dementia. Every diagnostic conclusion is revised by another doctor; in case of discrepancies a third geriatrician, chief of the study, intervenes to arbitrate.

All the instruments were pre tested for inter rater reliability in a similar population attending a geriatric day hospital, and some general agreement sessions were performed before and during the screening.

Study Type

Observational

Enrollment (Actual)

1321

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Milan
      • Abbiategrasso, Milan, Italy, 20081
        • Golgi Cenci Foundation

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

70 years to 75 years (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All the 1773 residents of Abbiategrasso, a town of 30.000 inhabitants near Milan, Lombardy, Italy, born from 1935 to 1939 : 1724 subjects meets the inclusion criteria

Description

Inclusion Criteria:

  • to be resident in Abbiategrasso
  • to be born between 1935 and 1939

Exclusion Criteria:

  • to refuse to participate
  • te be not contactable in any way (mail, telephone)
  • to be legally resident, but actually living somewhere else

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The proportion of the recruited persons who will develop Dementia syndrome, Alzheimer disease, Vascular dementia, Lewy Body dementia, frontotemporal dementia, Mild Cognitive Impairment, Cognitive Impairment No Dementia
Time Frame: six years

These are the criteria used for the definitions :

  • DSM IV for Dementia syndrome
  • NINCDS ADRDA diagnostic criteria for Alzheimer disease
  • NINDS -AIREN criteria for Vascular dementia
  • Third report, DLB consortium for Lewy Body dementia
  • 2002 modified Consensus Conference criteria for frontotemporal dementia
  • Report of the MCI Working Group of the European Consortium on Alzheimer's Disease for Mild Cognitive Impairment (MCI)
  • Absence of the first criteria for MCI (subjective complain) for the definition of Cognitive Impairment No Dementia (CIND)
six years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The proportion of persons who will exhibit a performance decrease equal or more than of 1,5 standard deviation of the mean in the reference population in screening cognitive tests or in memory tests (verbal and visual memory) or in executive tests
Time Frame: six years
  • Screening cognitive tests: Clock test and MMSE.
  • Memory tests: Babcock Story Recall Test , Rey 15-item Memory Test, and the Rey-Osterrieth Complex Figure Test (ROCF) recall.
  • Executive tests:Trial making A and B; copy of ROCF
six years
Neuropsychological baseline features of the persons who will develop dementia or cognitive impairment
Time Frame: six years
  • Mood: GDS 15 items
  • Verbal and visual memory: Babcock Story Recall Test, Rey 15-item Memory Test, and the Rey-Osterrieth Complex Figure Test (ROCF) recall
  • Executive function: TMTA and TMTB; copy of ROCF
  • Attention: Numerical Attention
  • Abstract reasoning: Raven's Coloured Progressive Matrices
  • Screening cognitive test: Clock test and MMSE
six years
Clinical baseline features of the persons who will develop dementia or cognitive impairment
Time Frame: six years
  • Index of co morbidities as defined by CIRS (Cumulative Index Rating Scale)
  • Standard neurological examination
six years
Social baseline features of the persons who will developed dementia or cognitive impairment
Time Frame: six years
  • Stressful life events as defined in GALES (Geriatric Adverse Life Event Scale)
  • Physical activity
  • Social network
six years
Genetic baseline features of the persons who will developed dementia and/or cognitive impairment
Time Frame: six years
  • ApoE
  • Inflammatory cytokines
six years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: ANTONIO GUAITA, MD, Golgi Cenci Foundation (research and study on aging)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2009

Primary Completion (Actual)

December 1, 2015

Study Completion (Actual)

December 1, 2015

Study Registration Dates

First Submitted

April 21, 2011

First Submitted That Met QC Criteria

April 28, 2011

First Posted (Estimate)

April 29, 2011

Study Record Updates

Last Update Posted (Estimate)

December 11, 2015

Last Update Submitted That Met QC Criteria

December 10, 2015

Last Verified

December 1, 2015

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dementia

3
Subscribe